---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-22-000028"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2022-10-25T23:59:59+00:00"
generated_at: "2026-06-23T01:31:11.812225+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance

## Summary
- Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).
- GAAP diluted EPS $7.84; Non-GAAP diluted EPS $4.77.
- Lecanemab Phase 3 Clarity AD met primary endpoint and all key secondary endpoints in early Alzheimer's.
- Tofersen NDA accepted with priority review; PDUFA date April 25, 2023.
- Company raises full year 2022 financial guidance.

## SEC filing metadata
- accession: 0000875045-22-000028
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2022-10-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/0000875045-22-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/biib-20221025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-22-000028
- JSON: https://secwatch.observer/filing/0000875045-22-000028.json
- Plain text: https://secwatch.observer/filing/0000875045-22-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.